Ozelle will present its automated hematology analyzer O-Cyte 1 at ADLM 2026, with both sources describing the event as a global debut and a step forward for AI-enabled hematology. The announcements state that O-Cyte 1 supports “morphology intelligence” powered by artificial intelligence and is positioned as an advancement of Ozelle’s hematology analysis platform, described as the fourth generation of Hematology Analysis. Both releases identify the same key timing and location details tied to ADLM 2026, including dates in late June 2026 and references to Anaheim, California and Frankfurt, Germany in the newswire distribution.
The two sources use closely aligned language, emphasizing increased speed and ongoing development of AI-based morphological analysis within hematology workflows. No additional clinical claims, performance metrics, regulatory status, or comparable product details are included in the provided excerpts. Overall, the information shared is limited to the planned ADLM 2026 debut of O-Cyte 1 and its intended role in accelerating AI-driven hematology morphology intelligence, framed as part of Ozelle’s fourth-generation analyzer development.
